Stocks & Investing
Tue, September 3, 2024
[ 12:00 AM ] - WOPRAI
Tue, August 13, 2024
[ 12:00 AM ] - WOPRAI
Thu, August 8, 2024
[ 12:00 AM ] - WOPRAI
Tue, August 6, 2024
[ 12:00 AM ] - WOPRAI
Wed, July 10, 2024
[ 12:00 AM ] - WOPRAI
Mon, July 8, 2024
[ 12:00 AM ] - WOPRAI
Tue, April 30, 2024
[ 12:00 AM ] - WOPRAI
Tue, April 23, 2024
[ 12:00 AM ] - WOPRAI
Tue, February 20, 2024
[ 12:00 AM ] - WOPRAI
Tue, February 6, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, November 27, 2023
[ 12:00 AM ] - WOPRAI
Tue, October 17, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, September 20, 2023
[ 12:00 AM ] - WOPRAI
Thu, July 6, 2023
[ 12:00 AM ] - WOPRAI
Mon, April 10, 2023
[ 12:00 AM ] - WOPRAI
Tue, December 6, 2022
[ 12:00 AM ] - WOPRAI
Thu, November 10, 2022
[ 12:00 AM ] - WOPRAI
Tue, June 14, 2022
[ 12:00 AM ] - WOPRAI
Ashwani Verma Maintained (TEVA) at Strong Buy with Increased Target to $26 on, Sep 3rd, 2024
Ashwani Verma of UBS, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Strong Buy with Increased Target from $24 to $26 on, Sep 3rd, 2024.
Ashwani has made no other calls on TEVA in the last 4 months.
There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 0 agree with Ashwani's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Ashwani
- Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $22 on, Thursday, August 1st, 2024
- Glen Santangelo of "Jefferies" Maintained at Strong Buy with Increased Target to $23 on, Thursday, June 27th, 2024
- Jason Gerberry of "B of A Securities" Maintained at Strong Buy with Increased Target to $21 on, Thursday, May 30th, 2024
- David Amsellem of "Piper Sandler" Reiterated at Buy with Increased Target to $20 on, Monday, May 13th, 2024
